Bocidelpar
- Generic Name
- Bocidelpar
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27F3N2O3
- CAS Number
- 2095128-20-2
- Unique Ingredient Identifier
- FKO8A7AD54
- Associated Conditions
- -
- Associated Therapies
- -
A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT05117294
- Locations
- ๐บ๐ธ
Advanced Pharma CR, LLC, Miami, Florida, United States
๐บ๐ธNucleus Network, Saint Paul, Minnesota, United States
๐บ๐ธPinnacle Research Group, Anniston, Alabama, United States
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04942964
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Inc, Orlando, Florida, United States
๐บ๐ธAdvanced Pharma CR, LLC, Miami, Florida, United States
๐บ๐ธTexas Liver Institute, San Antonio, Texas, United States
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04855201
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 34
- Registration Number
- NCT04641962
- Locations
- ๐บ๐ธ
University of California, San Diego, La Jolla, California, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธAkron Children's Hospital, Akron, Ohio, United States
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 8
- Registration Number
- NCT04184882
- Locations
- ๐บ๐ธ
Kennedy Krieger Institute, Baltimore, Maryland, United States
๐บ๐ธUniversity of California Davis Health, Sacramento, California, United States
๐บ๐ธUMass Memorial Medical Center, Worcester, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.